Liquidia Technologies

Home

Site Map

COMPANY

Liquidia Technologies is developing highly precise particle-based vaccines and therapeutics for the prevention and treatment of human disease. Combining a deep understanding of particle-based drug development with breakthrough small molecule and biological therapeutics, Liquidia is engineering vaccines and therapies that have the potential to dramatically improve the quality of human life. The company was founded in 2004 and is located in Research Triangle Park, North Carolina.
Learn more >

PRODUCT PLATFORM

Utilizing a novel platform known as PRINT® technology, Liquidia is designing highly specific carriers for delivery of small molecules and biological cargos. This breakthrough platform technology makes it possible for the first time to design vaccines and therapies with precise control of particle size, shape, and composition.
Learn more >

RECENT NEWS

May 15, 2012
Liquidia Studies Show PRINT® Engineered Particles Hold Promise in Inhaled Therapeutics Details

May 3, 2012
Liquidia Founder and UNC Professor Joseph DeSimone, Ph.D. Elected to NAS Details

April 18, 2012
Durham Company Hopes to Develop Many Applications Details

April 11, 2012
Liquidia CEO: Nanotech will outpace Biotech Details

April 4, 2012
Why nanotech will eclipse biotech in size and scope: a CEO’s perspectiveDetails

March 9, 2012
Particle Technology Delivers Medicines and Vaccines Details